Haleon plc (NYSE:HLN) Shares Purchased by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC boosted its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 13.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 750,897 shares of the company's stock after acquiring an additional 91,610 shares during the quarter. Janney Montgomery Scott LLC's holdings in Haleon were worth $7,944,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. AE Wealth Management LLC boosted its stake in shares of Haleon by 6.1% during the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company's stock worth $159,000 after acquiring an additional 1,098 shares during the period. Cardinal Capital Management boosted its holdings in Haleon by 2.5% in the second quarter. Cardinal Capital Management now owns 46,231 shares of the company's stock worth $382,000 after acquiring an additional 1,140 shares in the last quarter. Lake Street Advisors Group LLC increased its position in shares of Haleon by 5.4% during the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company's stock worth $237,000 after acquiring an additional 1,143 shares in the last quarter. Endowment Wealth Management Inc. lifted its holdings in shares of Haleon by 9.9% in the second quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company's stock valued at $106,000 after purchasing an additional 1,161 shares in the last quarter. Finally, Portside Wealth Group LLC boosted its holdings in Haleon by 2.7% during the 2nd quarter. Portside Wealth Group LLC now owns 44,985 shares of the company's stock worth $372,000 after acquiring an additional 1,182 shares during the last quarter. Institutional investors own 6.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HLN. UBS Group upgraded Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. The Goldman Sachs Group cut shares of Haleon from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. Morgan Stanley boosted their target price on shares of Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a report on Friday, September 20th. Finally, Berenberg Bank began coverage on Haleon in a report on Tuesday, August 6th. They set a "buy" rating on the stock. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $10.95.

Haleon Price Performance

HLN remained flat at $9.60 during trading hours on Friday. The company had a trading volume of 4,924,684 shares, compared to its average volume of 5,204,790. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company's 50-day moving average price is $10.21 and its 200-day moving average price is $9.29. The firm has a market capitalization of $43.46 billion, a price-to-earnings ratio of 28.22, a PEG ratio of 2.93 and a beta of 0.30. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.